← Vera Therapeutics overview

Vera Therapeutics vs Abcellera Biologics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Vera Therapeutics Inc (VERA)

Q2 2026
▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

  • FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.

    This is the single most important new event that directly answers why VERA is moving now.

  • FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.

    This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.

  • Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.

    Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.

  • Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.

    This provides a balanced view of the competitive landscape that could cap upside despite the approval.

June 2026
▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

  • FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.

    This is the single most important new event that directly answers why VERA is moving now.

  • FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.

    This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.

  • Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.

    Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.

  • Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.

    This provides a balanced view of the competitive landscape that could cap upside despite the approval.

Latest
▲3

Vera Wins FDA Accelerated Approval for TRUTAKNA, Eyes Full Approval

  • FDA Accelerated Approval of TRUTAKNA On July 7, the FDA granted accelerated approval to TRUTAKNA for IgA nephropathy, allowing Vera to sell the drug immediately. This is a major milestone that turns a pipeline story into a commercial one, boosting revenue prospects and investor confidence.

    This is the single most important new event that directly answers why VERA is moving now.

  • FDA Agreement on Earlier Kidney Function Analysis Vera reached an agreement with the FDA to analyze kidney function data earlier than planned, potentially supporting full approval. This could speed up the path to broader approval and expand the patient population, increasing the drug's market potential.

    This regulatory flexibility is a key new development that de-risks and accelerates the path to full approval.

  • Analyst Price Targets and PDUFA Anticipation Wells Fargo and LifeSci Capital reiterated Buy ratings with price targets of $70 and $90, citing atacicept's potential. Ahead of the July 7 PDUFA decision, the stock rose 6%, reflecting growing optimism about approval.

    Analyst support and pre-decision momentum highlight market expectations that drive near-term price action.

  • Intensifying Competition in IgA Nephropathy Over 25 companies are developing 30+ drugs for IgA nephropathy, with several late-stage candidates. While Vera's approval gives it a first-mover advantage, competition could pressure long-term pricing and market share.

    This provides a balanced view of the competitive landscape that could cap upside despite the approval.

Abcellera Biologics Inc (ABCL)

Q3 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

July 2026
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

Latest
▲2▼1

AbCellera's hot-flash drug success and Jazz deal offset weak Q2

  • Jazz partnership brings $56M upfront and up to $792M per program AbCellera signed a deal with Jazz Pharmaceuticals for two antibody programs for solid tumors, receiving $56 million upfront and potentially $792 million per program in milestones plus royalties. This validates its technology and adds non-dilutive cash, supporting the stock.

    This is a new partnership that directly boosts AbCellera's cash and validates its platform, driving positive sentiment.

  • Q2 loss widens to $55M as revenue falls to $4M AbCellera reported a wider net loss of $55 million and revenue dropped to $4 million from $17 million a year ago. The company also missed its internal goal of moving another program into IND-enabling activities, raising concerns about execution.

    This is a new financial report showing deteriorating results, which weighs on the stock price.

  • ABCL635 Phase 2 success sends stock up over 30% AbCellera's hot-flash drug ABCL635 met primary endpoints in a Phase 2 trial, reducing symptoms by 83% versus 33% for placebo with no serious side effects. The stock surged over 30%, as the drug could be a non-hormonal blockbuster.

    This is a major clinical win that directly caused a large stock jump and improves the company's pipeline prospects.

© 2026 MarketDXWhy